Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Toxicities Associated With VEGF TKIs and Checkpoint Inhibitors in mRCC

March 15th 2019

Heather Greene, a nurse practitioner at West Cancer Center, discusses the toxicities that are associated with VEGF TKIs and checkpoint inhibitors in metastatic renal cell carcinoma (mRCC).

Dr. McDermott on Single-Agent Versus Combination Immunotherapy in RCC

March 14th 2019

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses single-agent versus combination immunotherapy in the treatment of patients with renal cell carcinoma.

Dr. Agarwal on the Combination of Lenvatinib and Everolimus in mRCC

March 13th 2019

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses the combination of lenvatinib (Lenvima) and everolimus in the treatment of patients with metastatic renal cell carcinoma (mRCC).

Dr. Wright on Unmet Needs in Muscle-Invasive Bladder Cancer

March 12th 2019

Jonathan L. Wright, MD, MS, FACS, medical director of the University of Washington Medical Center Urology Clinic, associate professor of Urology at University of Washington, and affiliate investigator at the Fred Hutchinson Cancer Research Center, discusses unmet needs in muscle-invasive bladder cancer.

Dr. Powles on Rationale for KEYNOTE-426 in mRCC

March 11th 2019

Thomas Powles, MBBS, MRCP, MD, director, Barts Cancer Institute, discusses the rationale for the KEYNOTE-426 study in patients with metastatic renal cell carcinoma.

Pembrolizumab Plus Lenvatinib Elicits Responses in Urothelial Cancer

March 11th 2019

Combining lenvatinib and pembrolizumab led to a 25% overall response rate in patients with urothelial carcinoma and was associated with a manageable safety profile.

Dr. Grivas on Bladder Preservation in Localized Bladder Cancer

March 9th 2019

Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, oncology, University of Washington, Seattle Cancer Care Alliance, discusses data on bladder preservation in patients with localized bladder cancer.

Dr. Meric-Bernstam on CB-839 Plus Cabozantinib in RCC

March 8th 2019

Funda Meric-Bernstam, MD, chair, Department of Investigational Cancer Therapeutics, medical director, Institute for Personalized Cancer Therapy, professor of medicine, The University of Texas MD Anderson Cancer Center, discusses the combination of CB-839 plus cabozantinib in patients with renal cell carcinoma.

Dr. Pal on Molecular Signatures in Renal Cell Carcinoma

March 7th 2019

Sumanta Kumar Pal, MD, a medical oncologist at City of Hope, discusses the emergence of molecular signatures in patients with renal cell carcinoma (RCC).

Dr. Balar Discusses KEYNOTE-057 Study in NMIBC

March 6th 2019

Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses findings from the KEYNOTE-057 study presented at the 2019 Genitourinary Cancers Symposium.

Sacituzumab Govitecan Shows Early Promise in Urothelial Carcinoma

March 5th 2019

Scott T. Tagawa, MD, discusses the potential of sacituzumab govitecan in advanced urothelial cancers and reflects on progress made in prostate cancer.

Dr. Rini Discusses Tivozanib in Advanced RCC

March 2nd 2019

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the potential for tivozanib in patients with advanced renal cell carcinoma.

Dr. Agarwal Discusses Results of KEYNOTE-426 in mRCC

February 23rd 2019

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses findings from the KEYNOTE-426 study in patients with metastatic renal cell carcinoma.

Dr. McDermott on Single-Agent Pembrolizumab in Advanced RCC

February 19th 2019

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses single-agent pembrolizumab in the treatment of patients with advanced renal cell carcinoma.

Bempegaldesleukin/Nivolumab Combo May Address Unmet Need in Metastatic Urothelial Carcinoma

February 18th 2019

Arlene O. Siefker-Radtke, MD, discusses the promising preliminary data with bempegaldesleukin plus nivolumab in patients with metastatic urothelial carcinoma and the next steps for this combination.

Pembrolizumab Shows Promising Activity in Non-Clear Cell RCC

February 18th 2019

Single-agent pembrolizumab (Keytruda) showed encouraging antitumor activity as first-line treatment in patients with non-clear cell renal cell carcinoma, especially in those with papillary or unclassified histology.

Dr. Siefker-Radtke on Bempegaldesleukin Plus Nivolumab in Urothelial Carcinoma

February 17th 2019

Arlene O. Siefker-Radtke, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the promise of bempegaldesleukin plus nivolumab in the treatment of patients with metastatic urothelial carcinoma.

Modest Activity With Durvalumab/Savolitinib Combo in Papillary RCC Not Enough to Warrant Further Studies

February 17th 2019

The overall response rate achieved with with the combination of savolitinib and durvalumabin in patients with metastatic papillary renal cell carcinoma in the phase II CALYPSO study did not meet the prespecified criterion for further investigation of the regimen.

Pembrolizumab/Cabozantinib Combo Is Well Tolerated, Shows Activity in Metastatic RCC

February 17th 2019

The combination of pembrolizumab (Keytruda) and cabozantinib (Cabometyx) has antitumor activity in patients with previously treated metastatic renal cell carcinoma and is tolerated at their separate approved doses for this indication.

Sacituzumab Govitecan Active in Advanced Urothelial Carcinoma

February 16th 2019

Sacituzumab govitecan exhibited significant clinical activity in an open-label, single-arm phase I/II basket study of patients with heavily pretreated, relapsed/refractory metastatic urothelial cancer.